In a recently provided analysis from Frost & Sullivan, innovation and "therapeutic potential" have been seen with testing of Adult Stem Cells. As this article from MarketWatch informs:
"Adult stem cell therapies were traditionally thought to have poor therapeutic potential because they could only be produced in limited quantities or as needed. Now adult stem cells have the potential to become standardized pre-made therapies that can be mass produced."
This new data may prove to be a step forward in stem cell research, since many of the reasons for difficulty with this type of research surrounds the use of embryonic cells. Adult stem cells do not carry the same negative stigma.